Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.

Torrano J, Al Emran A, Hammerlindl H, Schaider H.

Clin Epigenetics. 2019 Mar 8;11(1):43. doi: 10.1186/s13148-019-0644-y. Review.


Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.

Emran AA, Chinna Chowdary BR, Ahmed F, Hammerlindl H, Huefner A, Haass NK, Schuehly W, Schaider H.

Cancer Med. 2019 Feb 21. doi: 10.1002/cam4.1978. [Epub ahead of print]


Distinct histone modifications denote early stress-induced drug tolerance in cancer.

Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H.

Oncotarget. 2017 Dec 24;9(9):8206-8222. doi: 10.18632/oncotarget.23654. eCollection 2018 Feb 2.


Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.

Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H.

Clin Cancer Res. 2018 Mar 1;24(5):1090-1102. doi: 10.1158/1078-0432.CCR-16-2118. Epub 2017 Dec 1.


Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.

Hammerlindl H, Schaider H.

J Cell Commun Signal. 2018 Mar;12(1):133-141. doi: 10.1007/s12079-017-0435-1. Epub 2017 Nov 30. Review.


Notch4 Signaling Induces a Mesenchymal-Epithelial-like Transition in Melanoma Cells to Suppress Malignant Behaviors.

Bonyadi Rad E, Hammerlindl H, Wels C, Popper U, Ravindran Menon D, Breiteneder H, Kitzwoegerer M, Hafner C, Herlyn M, Bergler H, Schaider H.

Cancer Res. 2016 Apr 1;76(7):1690-7. doi: 10.1158/0008-5472.CAN-15-1722. Epub 2016 Jan 22.

Supplemental Content

Loading ...
Support Center